Ecobiological composition capable of preventing and treating redness, signs of skin ageing, and vascular anomalies
Patent Information
- Application Number
- HK62026126250
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-10-27
- Filing Date
- 2026-07-16
- Publication Date
- 2026-09-11
Smart Images

Figure 00000032_0000 
Figure 00000059_0000
Abstract
Description
(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480068955.2 (22) Application Date 2024.10.25 (30) Priority Data FR2311764 2023.10.27 FR (85) PCT International Application Entering National Phase Date 2026.04.27 (86) PCT International Application Application Data PCT / FR2024 / 051416 2024.10.25 (87) PCT International Application Publication Data WO2025 / 088286 FR 2025.05.01 (71) Applicant: Naus Life Sciences Institute Address: France Applicant: Jean-Noël Torrel (72) Inventor: Jean-Noël Torrel (74) Patent Agency: Beijing Pinyuan Patent Agency Co., Ltd. 11332 Patent Attorneys Liu Minghai and Hu Bin (51) Int.Cl. A61K 8 / 64 (2006.01) A61K 8 / 88 (2006.01) A61K 31 / 405 (2006.01) A61P 17 / 00 (2006.01) A61Q 19 / 08 (2006.01) A61K 38 / 05 (2006.01) (54) Title of Invention: An Ecobiological Composition for the Prevention and Treatment of Redness, Signs of Skin Aging, and Vascular Abnormalities (57) Abstract: This invention relates to a cosmetic composition, advantageously an ecobiological cosmetic composition, comprising: - polyglutamic acid or a salt thereof; and - at least one peptide derivative represented by general formula (I), wherein: - R1 represents a hydrogen atom, an acyl radical, or an acyloxy radical; and - R2 represents a side chain of an α-amino acid selected from the group consisting of tryptophan, glutamic acid, arginine, cysteine, methionine, histidine, and tyrosine. The invention also relates to the use of said cosmetic composition for combating skin redness and / or skin aging; to its use for preventing and / or combating excessive vascularization of the skin and / or skin inflammation and / or rosacea; and to methods for selecting compounds suitable for preventing and / or combating these conditions. Claims 2 pages, Description 17 pages, Drawings 1 page CN 122180498 A 2026.06.09 CN 1 22 18 04 98 A 1. A topical composition, advantageously an ecobiological topical composition, comprising: - one of polyglutamic acid or a salt thereof; and - at least one peptide derivative represented by the following general formula (I): wherein: - R1 represents a hydrogen atom, an acyl radical or an acyloxy radical; and - R2 represents a side chain of an α-amino acid selected from the group consisting of tryptophan, glutamic acid, arginine, cysteine, methionine, histidine and tyrosine.2. The composition according to claim 1, characterized in that the molecular weight (Mw) of the polyglutamic acid or one of its salts is from 0.01 kDa to 10 kDa, advantageously from 0.1 kDa to 5 kDa. 3. The composition according to claim 1 or 2, characterized in that one of the polyglutamic acid or its salts is poly-γ-glutamic acid, advantageously a potassium salt of poly-γ-glutamic acid. 4. The composition according to any of the preceding claims, characterized in that the at least one peptide derivative is selected from the group consisting of α-L-glutamine, L-tryptophan and L-methionine, advantageously α-L-glutamine. 5. The composition according to any one of the preceding claims, characterized in that: - the polyglutamic acid or one of its salts corresponds to the following INCI names: polyglutamic acid, sodium polyglutamate, natto gum, or hydrolyzed poly-γ-glutamate potassium; and / or - the at least one peptide derivative is α-L-glutamyltryptamine, which corresponds to CAS number 478273-36-8 ((4S)-4-amino-5-[[2-(1H-indol-3-yl)ethyl]amino]-5-oxovalerate) and / or corresponds to the INCI name glutamylaminoethylindole. 6. The composition according to any one of the preceding claims, characterized in that the weight ratio of the at least one peptide derivative to polyglutamic acid or one of its salts is 1:200 to 1:10, advantageously 1:100 to 1:30. 7. The composition according to any one of the preceding claims, characterized in that: - the polyglutamic acid or one of its salts accounts for 0.001% to 10% of the total weight of the composition, advantageously 0.01% to 5%, preferably 0.1% to 2%; and / or - the at least one peptide derivative accounts for 0.00001% to 10% of the total weight of the composition, advantageously 0.0001% to 1%. 8. The composition according to any one of claims 1 to 7 for non-medical use in combating skin redness and / or skin aging. 9. The composition according to any one of claims 1 to 7 for the prevention and / or treatment of: - excessive angiogenesis in the skin; and / or - skin inflammation; and / or - rosacea. 10. An in vitro or ex vivo method for selecting a compound or mixture of compounds, comprising the steps of: a) measuring the content of PEDF protein (pigment epithelium-derived factor) and / or PEDF-encoded nucleic acid in at least one skin cell and / or extracellular space, referred to as a reference value; b) inhibiting PEDF synthesis by exposure to ultraviolet (UV) light; c) contacting the compound or mixture of compounds with the skin cells; d) measuring the content of PEDF protein and / or PEDF-encoded nucleic acid in the skin cells and / or extracellular space, referred to as a "candidate compound" value;e) Compare the “candidate compound” value obtained in step d) with the reference value obtained in step a); f) When an increase in the content of PEDF and / or PEDF-encoded nucleic acid is observed in step e), select the compound or a mixture of compounds. 11. The method according to claim 10, wherein the exposure to UV is obtained by: - exposure to UVA, preferably at 750 W / m², with a surface energy of 7.5 J / cm² to 80 J / cm²; or - exposure to the full solar spectrum, preferably at 750 W / m², with a surface energy of 7.5 J / cm² to 80 J / cm². Claims 2 / 2 Page 3 CN 122180498 A Ecological biological composition capable of preventing and treating redness, signs of skin aging and vascular abnormalities Technical Field
[0001] This invention relates to the field of cosmetics, and particularly to cosmetic compositions, advantageously ecological biological cosmetic compositions, and their use in effectively combating skin aging, especially photoaging, aging of skin prone to redness, vascular abnormalities associated with skin aging, and skin inflammation associated with redness, particularly redness associated with hypervascularization, skin inflammation and rosacea. Background Art
[0002] The skin constitutes the main barrier separating an organism from the external environment and comprises a superposition of three main layers and a surface layer, from deepest to outermost: subcutaneous tissue, dermis and epidermis, with the epidermis colonized by microbiota and often considered the final "skin layer". Because the skin constantly interacts with the environment, it is subjected to multiple attacks that disrupt its balance. Various exogenous and endogenous factors can occasionally lead to significant differences in the level of skin irritability between individuals. Therefore, more and more people believe that their skin is prone to redness, usually chronic redness.
[0003] Skin redness, also known as erythema, is a common condition characterized by an abnormal red or pinkish hue of the skin. It can be caused by a variety of factors, such as sun exposure, vascular abnormalities, allergic reactions, irritation, or actually hormonal changes. The chronic form of redness is often referred to as rosacea erythematosus. This is a skin condition characterized by persistent redness, vasodilation, significant hypervascularization of the skin, papules, and inflammatory plaques on the face (especially the cheeks, chin, nose, and forehead). Whether temporary or chronic, skin redness is a source of aesthetic distress, discomfort, and even social embarrassment (sometimes leading to withdrawal).
[0004] Hypervascularization of the skin refers to a condition in which the number and size of blood vessels in the skin are abnormally increased. Skin with hypervascularization is usually more sensitive and reactive, leading to itching, irritation, or even pain. In addition to sensory symptoms, hypervascularization of the skin often has aesthetic effects. Areas of skin with hypervascularization remain red, even if the skin does not have any other symptoms.Inflammation can cause blood vessels to appear as red lines. In some cases, this can affect an individual's self-confidence and quality of life. Furthermore, vascular abnormalities tend to become increasingly prominent with skin aging, particularly due to the gradual reduction in the thickness of the epidermis, the thickness of the dermal extracellular matrix that protects and surrounds blood vessels, and the decrease in natural biological resources for skin maintenance, function, and defense.
[0005] In particular, skin redness and / or erythematous acne are caused by a complex set of factors, including, in particular, age and an individual's overall health. Therefore, it is difficult to propose skin treatments that can act synergistically on the causes of these heterogeneous skin conditions.
[0006] Based on its ecobiological approach, the applicant has identified and acted upon the causes of skin conditions, particularly by modulating the function of key epidermal and dermal regulatory factors to act on multiple aspects simultaneously. In recent years, particularly in the skin, PEDF proteins have been identified as one of these factors that play a major role in controlling inflammation, skin redness, and especially excessive vascularization of the skin.
[0007] PEDF protein, also known as “pigment epithelium-derived factor” (i.e., factor derived from pigment epithelium), belongs to the group of non-inhibitory serine protease inhibitors (serpins). This 50 kDa protein containing 398 amino acids is a secreted glycoprotein (Filleur et al., 2009), primarily produced by retinoblastoma epithelial cells (Tombran-Tink et al., 2004), but it is also present in other tissues, including the skin (Yan et al., 2018). PEDF protein has multiple functions in the skin. First, it participates in the regulation of cell differentiation and promotes the maturation of keratinocytes, while maintaining a balance between proliferation and cell differentiation in the epidermis (Belkacemi and Zhang, 2016). Furthermore, PEDF protein is known for its anti-inflammatory activity and ability to regulate skin immune responses. It can inhibit the expression of pro-inflammatory cytokines and reduce the penetration of immune cells into the skin, which helps alleviate inflammatory skin responses (Zamiri et al., 2006). Furthermore, PEDF protein possesses important anti-angiogenic properties; more precisely, PEDF regulates angiogenesis homeostasis by inhibiting VEGF synthesis (Filleur et al., 2009; Yan et al., 2018). Other useful properties of PEDF include its ability to inhibit the expression of metalloproteinases MMP-2 and MMP-9 in human pancreatic cancer cell lines in vitro (Grippo et al., 2012), its ability to inhibit the expression of MMP MT1-MMP (also known as MMP-14) in human chondrosarcoma cell lines in vitro (Tan et al., 2010), and its ability to inhibit ROS (reactive oxygen species) production (Yamagishi et al., 2018).
[0008] However, PEDF expression decreases with age, particularly from age 30 onwards, for example, this age is positively correlated with the onset of rosacea (Francis et al., 2004).
[0009] In general, PEDF proteins play a key role in maintaining skin integrity and function by modulating various cellular processes, thereby contributing to the regulation of immune and inflammatory responses in the skin, or in fact, particularly by acting on the main causes of skin redness (e.g., inflammation and excessive angiogenesis).
[0010] Therefore, the literature EP 2 897 976 proposes the topical use of PEDF-derived peptides to combat skin inflammation and aging. However, formulating PEDF or one of its fragments into cosmetic compositions, particularly for topical use, is difficult due to issues of stability, bioavailability, lack of skin penetration, and maintenance of skin surface bioactivity, as these peptides are rapidly inactivated by the skin microbiota and skin proteases.
[0011] Therefore, there remains an urgent need, particularly based on the principles of ecobiology, to develop (i) compositions that protect and / or restore skin balance to ultimately improve the aesthetic appearance and social life of subjects suffering from skin redness and / or rosacea and / or excessive vascularization and / or skin inflammation and / or aging, especially photoaging and / or vascular abnormalities associated with skin aging, and (ii) methods for identifying and selecting compounds or active ingredients capable of preventing and / or treating said skin redness and / or said rosacea and / or said aging to protect and / or restore skin balance. Summary of the Invention
[0012] After extensive research, it is commendable that the applicant has unexpectedly and surprisingly discovered a composition comprising a combination of multiple compounds (or active ingredients) that synergistically satisfy the above-mentioned needs. Furthermore, it is equally commendable that the applicant has identified an innovative method for selecting said compounds by implementing a surprising PEDF content inhibition step.
[0013] According to the ecobiological approach to addressing the biological causes of skin conditions, one object of the present invention is to protect and / or restore skin balance by preventing and / or treating skin redness, excessive angiogenesis, skin inflammation and / or rosacea and / or skin aging, particularly vascular abnormalities associated with skin aging (or vascular aging), especially photoaging, while utilizing endogenous mechanisms, particularly by acting on an increase or restoration of endogenous PEDF content.
[0014] Therefore, the first object of the present invention relates to a topical composition, advantageously an ecobiological topical composition, comprising:
[0015] - one of polyglutamic acid or a salt thereof; and
[0016] - at least one peptide derivative represented by the following general formula (I): Specification 2 / 17 pages 5 CN 122180498 A
[0017]
[0018] Wherein:
[0019] - R1 represents a hydrogen atom, an acyl radical, or an acyloxy radical; and
[0020] - R2 represents a side chain of an α-amino acid selected from the group consisting of tryptophan, glutamic acid, arginine, cysteine, methionine, histidine, and tyrosine.
[0021] According to one embodiment, it is a cosmetic composition, advantageously an ecobiological cosmetic composition, in a form suitable for topical application.
[0022] According to one embodiment, R2 represents a side chain of an α-amino acid selected from the group consisting of: L-tryptophan, L-glutamic acid, L-arginine, L-cysteine, L-methionine, L-histidine, and L-tyrosine.
[0023] The present invention provides several advantages, in particular:
[0024] (i) it allows for the simple use of an effective composition, which can be integrated into routine procedures, wherein the compounds of the composition can work synergistically to prevent and / or treat the aforementioned skin dysfunctions;
[0025] (ii) it respects the living cell communities that constitute the skin, which constantly interact with each other and with their environment to maintain the balance of the skin ecosystem;
[0026] (iii) it can be used to protect and / or restore the balance of the skin; and
[0027] (iv) it is inexpensive.
[0028] In particular, the present invention is especially capable of:
[0029] - preventing and / or combating skin redness, and / or;
[0030] - preventing and / or combating skin aging, especially photoaging; and / or
[0031] - preventing and / or combating excessive proliferation of skin blood vessels; and / or
[0032] - preventing and / or combating skin inflammation; and / or
[0033] - preventing and / or treating rosacea; and / or
[0034] - protecting and / or restoring the balance of the skin; and / or
[0035] - protecting against skin effects related to UV radiation; and / or
[0036] - preventing and / or combating vascular abnormalities related to skin aging; and / or
[0037] - protecting against skin effects related to the environment, especially pollution.
[0038] In the context of this invention, the terms "ecological biological composition," "ecological biological active ingredient," or "ecological biological excipient" refer to compositions, ingredients, or excipients that respect humans, their interactions with the world, and the earth. In other words, this refers to compositions, active ingredients, or (in fact) excipients that respect the homeostasis of an individual, their interactions with the world, and the environment. Specifically, it refers to compositions, active ingredients, or (in fact) excipients that respect the living cellular communities that constitute the skin (i.e., the skin microbiome, keratinocytes, fibroblasts, etc.) and the continuous interactions between these living cellular communities and with the environment to maintain the homeostasis / balance of this skin ecosystem.
[0039] In the context of this invention, the expression "ecological biological method" refers to a specific method pioneered by the inventors and developed by the applicant, which combines skin biology and ecosystems to help the skin grow in accordance with its natural biological specifications 3 / 17 page 6 CN 122180498 A.
[0040] In the context of this invention, the expression "polyglutamic acid and its salts" refers to a polymer containing glutamic acid monomers, glutamic acid being an amino acid present as a component of proteins in all organisms on Earth.
[0041] In the context of this invention, the terms "inducer" and "PEDF synthesis inducer" are used interchangeably, referring to reagents, treatments, or culture conditions capable of initiating a specific reaction or programmed reaction sequence in a biological system, i.e., the production or synthesis (i.e., transcription and / or translation) of PEDF.
[0042] In the context of this invention, the terms "active compound," "active ingredient," and "active element (principe)" are used interchangeably, referring to a substance or compound having biological and / or medical properties that constitute the basis of physiological effects. The active compound, active ingredient, or active element should be distinguished from at least one excipient present in the composition according to the invention.
[0043] In the context of this invention, the term "excipient" refers to a substance or compound that does not have any biological and / or medical properties. The excipient ensures that the cosmetic formulation produces a specific texture, fragrance, and / or color, and ensures that its shelf life, stability, safety, and expiration date meet specifications. The excipient should be distinguished from at least one active compound, active ingredient, or active element present in the compositions of this invention.
[0044] In the context of this invention, the term "molecular weight (Mw)" refers to the mass average molecular weight (Mw or "molecular weight") of a compound, protein, or another advantageous natural polymer such as polyglutamic acid and its salts.
[0045] In the context of this invention, the expression "composition for skin application" or "composition for topical application" refers to a composition compatible with application to the skin, mucous membranes, hair, and / or scalp, preferably human skin.
[0046] In the context of this invention, the term "care" refers to cosmetic and non-medical care.
[0047] In the context of this invention, the expression “contact with at least one skin cell” refers to any direct exposure (e.g., cultured cells) or indirect exposure (e.g., topical application) to the at least one candidate compound according to the invention. In particular, indirect exposure by topical application can be performed on the entire living (advantageously human) skin, on a skin explant, on reconstructed epidermis, or on reconstructed skin. Preferably, indirect exposure is performed on a skin explant, reconstructed epidermis, or reconstructed skin.
[0048] In the context of this invention, the expression “skin explant” refers to a biopsy of human skin obtained from surgical waste, comprising the entire epidermis and dermis and / or subcutaneous tissue sections.
[0049] In the context of this invention, the term "skin substitute" refers to reconstructed skin or reconstructed epidermis, preferably human reconstructed skin or reconstructed epidermis, comprising differentiated cells distributed in multiple layers. Specifically, in the context of this invention, the reconstructed skin comprises at least two partitions: a dermal partition and an epidermal partition. These models can be generated by 3D printing or cell differentiation and can include a variety of cell types to approximate the full functionality (nervation, immunity, pigmentation, angiogenesis, etc.) of human or animal epidermis as closely as possible. Examples of suitable models of this type are sold by LabSkin Creations, or in fact by Straticell, SkinEthic, Episkin, or Phenion.
[0050] In the context of this invention, the term "reconstructed epidermis" refers to epidermis generated in vitro using conventional techniques well known to those skilled in the art (e.g., Limat and Hunziker, 2002; Poumay et al., 2004). Advantageously, the keratinocytes used in this epidermis are obtained from the skin of humans suffering from sensitive / rosacea.
[0051] In the context of this invention, the term "reconstructed skin" refers to an epidermal component comprising in vitro generated keratinocytes and a dermal component comprising in vitro generated fibroblasts, which are integrated into the dermal matrix tissue. The reconstructed skin is commercially available. Advantageously, the keratinocytes and fibroblasts used in such skin can be derived from the skin of a human with sensitive / rosacea-like skin, more advantageously from sensitive skin.
[0052] In the context of this invention, the term "skin cell" refers to any cell type present at least partially in one of the three layers of the skin, namely, epidermal cells (e.g., keratinocytes, melanocytes, Merkel cells, immune cells such as Langerhans cells, C-type nerve endings), dermal cells (e.g., mast cells, vascular smooth muscle cells, specialized myocytes, fibroblasts and immune cells, dermal dendritic cells, fibroblasts, endothelial cells), subcutaneous cells (e.g., adipocytes), nerve cells, and macrophages. It is evident that, according to the invention, the expression "skin cells" includes any nerve cells present in the skin as terminals or fibers. In particular, the skin cells are fibroblasts or keratinocytes, advantageously of human origin.
[0053] In the context of the invention, the expressions "reference value," "normal value," "normal," "standard," "usual value," or "reference biological sample" are used interchangeably to refer to the value or average of a parameter (e.g., gene expression, particularly at the mRNA level, etc.) obtained from one or more subjects, and represent a baseline state of the expected measurement; and are consistent with "value tested," "test value," "test result," etc.The values for "selected compounds" or "tested biological samples" are relative. Reference values and test values are obtained by performing the same detection, quantification, identification, and other methods.
[0054] In the context of this invention, the terms "content," "amount," and "level" are used interchangeably.
[0055] In the context of this invention, the terms "PEDF protein" and "PEDF" are used interchangeably.
[0056] In the context of this invention, the expression "endogenous skin content of PEDF and / or nucleic acid encoding it" or "content of PEDF and / or PEDF-encoded nucleic acid" refers to the level present in skin cells and / or extracellular media after secretion by the skin cells under normal conditions, particularly under normal culture conditions, and without inducing or eliminating PEDF expression.
[0057] In the context of this invention, the expression "extracellular space," "extracellular matrix," "extracellular media," or "supernatant" refers to the space outside the cells. This space is considered to be outside the plasma membrane. This term is the opposite of "intracellular," which refers to the interior of the cell.
[0058] In the context of this invention, the expression "variation in expression" refers to overexpression or underexpression of a gene. Specifically, the term "overexpression" means an increase in gene expression relative to a reference value; the term "underexpression" means a decrease in gene expression relative to a reference value.
[0059] The term "encoding" (or "coding for") is used interchangeably and refers to the inherent characteristic of a specific nucleotide sequence in a polynucleotide (such as a gene, cDNA, or mRNA), i.e., serving as a template for the synthesis of a polypeptide having a defined amino acid sequence and the resulting biological characteristics. Thus, if the transcription and translation of mRNA corresponding to a gene produces a protein in a cell or another biological system, then the gene encodes that protein. Both the coding strand (whose nucleotide sequence is identical to the mRNA sequence and is typically described in sequence listings and databases) and the non-coding strand (serving as a template for gene or cDNA transcription) can be referred to as the protein or another product encoding that gene or cDNA.
[0060] In the context of this invention, the term "bioactive derivative" refers to isomers, fragments, or modified forms of isomers or fragments, particularly those covalently modified by grafting organic groups (such as octanoyl, stearoyl, palmitoyl fatty chains, or actually by acetylation, methylation, etc.). Such derivatives may exhibit biological activities similar to or even superior to those of the proteins from which they originate.
[0061] In the context of this invention, all embodiments described below can be combined.
[0062] According to one specific embodiment, the molecular weight (Mw) of at least one polyglutamic acid or its salt according to the invention is from 0.1 MDa to 20 MDa, advantageously from 1 MDa to 5 MDa.
[0063] According to another specific embodiment, the molecular weight (Mw) of at least one polyglutamic acid or salt thereof according to the invention is from 0.01 kDa to 10 kDa, advantageously from 0.1 kDa to 5 kDa.
[0064] According to another specific embodiment, one of the at least one polyglutamic acid or salt thereof according to the invention is poly-γ-glutamic acid, advantageously a potassium salt of poly-γ-glutamic acid. Specification 5 / 17 pages 8 CN 122180498 A
[0065] In particular, one of the polyglutamic acid or salt thereof corresponds to the following INCI names: polyglutamic acid, sodium polyglutamate, natto gum or hydrolyzed potassium poly-γ-glutamic acid.
[0066] According to the invention, one of the at least one polyglutamic acid or salt thereof is a synthetic poly-γ-glutamic acid of plant or microbial origin, for example, synthesized by Bacillus subtilis subsp. Chungkookjang or other similar bacterial strains.
[0067] In particular, at least one polyglutamic acid or salt thereof according to the invention corresponds to the following starting materials: AminoPGALE®-301 sold by Toyobo Co. LTD; AquaMax™ HM sold by CP Kelco; sodium polyglutamate sold by Vedan Biotechnology Corporation; TEGO® Cosmo PGA sold by Evonik Nutrition & Care GmbH; or Gamma-Max or more specifically Gamma-Oligo sold by Rahn Corporation. Preferably, it is a Gamma-Oligo starting material sold by Rahn Corporation.
[0068] According to a specific embodiment, the at least one peptide derivative is selected from the group consisting of α-L-glutamyltryptamine, L-tryptamine, and L-methionine.
[0069] Advantageously, the at least one peptide derivative is α-L-glutamyltryptamine, preferably corresponding to α-L-glutamyltryptamine of CAS No. 478273-36-8 ((4S)-4-amino-5-[[2-(1H-indole-3-yl)ethyl]amino]-5-oxovaleric acid) and / or INCI name glutamylaminoethylindole.
[0070] In particular, the at least one peptide derivative corresponds to GLISTIN, a cosmetic starting material sold by EXSYMOL under INCI name glutamylaminoethylindole (and) propylene glycol (and) water.
[0071] According to a specific embodiment, the composition of the present invention contains at least one peptide derivative and polyglutamic acid or thereof.The weight ratio of one of the salts is 1:200 to 1:10, advantageously 1:100 to 1:30.
[0072] According to a specific embodiment, the composition of the present invention comprises:
[0073] - one of polyglutamic acid or a salt thereof, comprising 0.001% to 10% of the total weight of the composition, advantageously 0.01% to 5%, preferably 0.1% to 2%; and / or
[0074] - at least one peptide derivative, comprising 0.00001% to 10% of the total weight of the composition, advantageously 0.0001% to 1%.
[0075] Advantageously, the compositions according to the invention, alone or in combination, have the following additional technical features:
[0076] - The compositions according to the invention further comprise at least one additional compound selected from the group consisting of: glycyrrhetinic acid, a derivative or salt of the acid; hyaluronic acid or one of its salts or one of its derivatives; psoralen; dipotassium glycyrrhizate, acetyl dipeptide-1 cetyl ester; squalane; jojoba oil; fructooligosaccharides; rhamnose; mannitol; xylitol; ectoine, and mixtures thereof;
[0077] - The compositions according to the invention comprise glycyrrhetinic acid, a derivative or salt of the acid, preferably from 0.01% to 2% of the total weight of the composition, advantageously from 0.1% to 1% of the total weight of the composition;
[0078] - The compositions according to the invention comprise hyaluronic acid or one of its salts or one of its derivatives, advantageously wherein:
[0079] the hyaluronic acid is in the form of an acid or salt, particularly a sodium, potassium or magnesium salt, preferably a sodium salt;
[0080] The molecular weight (Mw) of one of the hyaluronic acid or its salts is 0.1 kDa to 2 MDa, preferably 400 to 600 kDa or 0.1 to 5 KDa;
[0081] The hyaluronic acid or its salts account for 0.0001% to 10% of the total weight of the composition, advantageously 0.001% to 2% of the total weight of the composition, more advantageously 0.01% to 1% of the total weight of the composition;
[0082] The hyaluronic acid or its salts correspond to the starting material BIOSODIUM HYALURONATE sold by DKSH, page 6 / 17, 9 CN 122180498 A MMW, which corresponds to the INCI name sodium hyaluronate;
[0083] The composition according to the invention also comprises a bioactive system that, on the one hand, binds to the stable form in aqueous solution of a nucleotide selected from ATP (adenosine triphosphate), Gp4G (guanosine tetraphosphate) and Ap4A (adenosine tetraphosphate); On the other hand, it can be combined with at least one biomimetic peptide containing up to six amino acids, said biomimetic peptide mimicking skin polypeptides or skin proteins, or biomolecules that are agonists or antagonists of said peptides or proteins. This bioactive system can be used to catalyze...This process modulates the metabolic activity of skin cells and achieves cosmetic or therapeutic effects through the use of biomimetic peptides. The latter can be selectively chosen to obtain desired results, such as inhibiting neurogenic stimulation, depigmentation activity, or suppressing any intolerances or sensitization.
[0084] In the bioactive system according to the invention, advantageously, the nucleotide accounts for at most 10% of the total weight of the composition, preferably from 0.001% to 5% of the total weight of the composition; and the biomimetic peptide accounts for 0.001% to 1% of the total weight of the composition;
[0085] - The composition according to the invention contains a compound that contributes to internal protection through some action, which may include: DNA protection, reduction of immunosuppression induced by UV irradiation, free radical scavenging, or a combination of these actions;
[0086] - The composition according to the invention contains a free radical scavenger that maintains cell structure, such as vitamin E and / or its fat-soluble or water-soluble derivatives, particularly tocotrienols and / or tocopherols, which advantageously account for 0.001% to 10% of the total weight of the composition, more advantageously from 0.02% to 2% of the total weight of the composition, preferably 0.04%;
[0087] - The composition according to the invention further contains at least one compound selected from the group consisting of: fructooligosaccharides, boldo extract, carnosine, adenosine, creatinine, and creatine;
[0088] - The composition according to the invention comprises Peumus boldus or an extract of Peumus boldus. Peumus boldus is a tree from the Monimiaceae family, whose leaf extract induces the synthesis of defensins and cathelicidin. Advantageously, the Bordeaux tree extract comprises 0.0001% to 10% of the total weight of the composition, more advantageously 0.001% to 2% of the total weight of the composition, and preferably 0.01% to 1% of the total weight of the composition;
[0089] The Bordeaux tree extract in the composition according to the invention advantageously corresponds to the starting material MP BETAPUR PGF sold by BASF, which corresponds to the INCI name water (and) butylene glycol (and) Bordeaux leaf extract (and) pentane glycol (and) xanthan gum (WATER (AND) BUTYLENE GLYCOL (AND) PEUMUS BOLDUS LEAF EXTRACT (AND) PENTYLENE GLYCOL (AND) XANTHAN GUM);
[0090] The composition according to the invention contains adenosine, advantageously comprising 0.0001% to 5% of the total weight of the composition, more advantageously 0.001% to 1% of the total weight of the composition, and preferably 0.01% to 0.05%;
[0091] The adenosine in the compositions according to the invention is advantageously in a non-phosphorylated form, more advantageously in powder form, andAnd it can correspond to the INCI name adenosine sold by PHARMA WALDHOF;
[0092] - The composition according to the invention comprises carnosine, advantageously accounting for 0.001% to 5% of the total weight of the composition, more advantageously accounting for 0.01% to 1%;
[0093] The carnosine in the composition according to the invention is preferably in a purified or highly purified form, advantageously obtained by chemical synthesis, and can be the starting material Kopsine sold by KUMAR ORGANIC PRODUCTS LTD, corresponding to the INCI name carnosine;
[0094] - The composition according to the invention comprises creatinine, which advantageously accounts for 0.001% to 5% of the total weight of the composition, more advantageously accounting for 0.01% to 1% of the total weight of the composition;
[0095] The creatinine in the composition according to the invention is advantageously in a purified or highly purified form, more advantageously obtained by chemical synthesis, and can be the starting material TEGO COSMO C 250 sold by EVONIK, corresponding to the INCI name specification page 7 / 17 10 CN. 122180498 A METHYLHYDANTOIN-2-IMIDE;
[0096] - The composition according to the invention comprises fructo-oligosaccharide, also known as oligofructose or FOS, which advantageously constitutes 0.001% to 10% of the total weight of the composition, preferably 0.01% to 5% of the total weight of the composition;
[0097] The FOS in the composition according to the invention is advantageously in a purified or highly purified form and may correspond to the starting material fructo-oligosaccharide sold by SHAANXI BOLIN BIOTECHNOLOGY CO, which corresponds to the INCI name FRUCTOOLIGOSACCHARIDES;
[0098] - The composition according to the invention further comprises peptide extracts from soybeans and / or wheat, which advantageously constitute 0.01% to 20% of the total weight of the composition, more advantageously 0.1% to 10%;
[0099] The peptide extracts from soybeans and wheat in the compositions according to the invention advantageously have a weight ratio between 80 / 20 and 20 / 80, more advantageously between 70 / 30 and 30 / 70, and preferably equal to 60 / 40;
[0100] The peptide extracts from soybeans and / or wheat in the compositions according to the invention preferably do not contain synthetic GHK tripeptide (glycyl-histyl-lysine; INCI: Tripeptide-1);
[0101] The soybean peptide extract in the compositions according to the invention can be an extract identified by CAS number 68607-88-5.The composition according to the invention may be an extract identified by CAS number 70084-87-6; advantageously, it corresponds to the INCI name HYDROLYZED SOY PROTEIN;
[0102] The wheat peptide extract in the composition according to the invention may be an extract identified by CAS number 70084-87-6; advantageously, it corresponds to the INCI name HYDROLYZED WHEAT PROTEIN;
[0103] - The composition according to the invention comprises at least one branched hydrogenated glucose homopolymer containing α (1-4) and α (1-6) bonds, which advantageously accounts for 0.001% to 2% by weight of the composition, more advantageously 0.01% to 0.5%;
[0104] - The composition according to the invention contains α (1-4) and α (1-6)-branched hydrogenated glucose homopolymers advantageously correspond to the INCI name hydrogenated starch hydrolysate, more advantageously to the starting material MG-60 sold by HAYASHIBARA, and correspond to the INCI name maltooligosyl Glucoside & Hydrogenated Starch Hydrolysate;
[0105] - The composition according to the invention comprises a heteropolymer of at least one glucose and trehalose, advantageously maltooligosyl glucoside, more advantageously accounting for 0.001% to 2% by weight of the composition, more advantageously accounting for 0.01% to 0.5%.
[0106] According to a specific embodiment, the composition according to the invention is an acceptable galen formulation suitable for cosmetic use, i.e., compatible with skin, mucous membranes, hair, and scalp.
[0107] In particular, the composition is a galen formulation suitable for skin application and / or topical application.
[0108] Therefore, the compositions according to the invention can be in the form of aqueous solutions, hydroalcoholic solutions, organic solutions, or oily solutions; suspending or dispersing agents or serums in solvents or fats; vesicle dispersants; or water-in-oil (W / O) emulsions, oil-in-water (O / W) emulsions, or multiple emulsions such as water-in-oil-in-water (W / O / W) emulsions. The emulsions can have a greater or lesser thickness and are in the form of creams or lotions; the compositions of the invention can also be in the form of ointments, gels, solid rods, pastes, or solid anhydrous products, foams (especially aerosols), two-phase compositions, or even sprayable compositions.
[0109] The galenal formulation of the compositions and its preparation method, as well as the corresponding excipients suitable for the compositions of the invention, can be selected by those skilled in the art based on their general knowledge according to the type of composition sought. In particular, the compositions can include any fats conventionally used in the cosmetics field. In particular, references can be made to, for example, plant, mineral, animal...The composition comprises fats and / or oils and waxes of synthetic origin. The oils may be volatile or non-volatile. Synthetic esters and ethers, fatty alcohols, and fatty acids may also be mentioned. The composition may also contain an aqueous medium, a water-alcohol medium containing alcohols (such as ethanol or isopropanol), or an organic medium containing common organic solvents (such as C1-6 alcohols (especially ethanol and isopropanol), glycols (such as propylene glycol), and ketones). It will be apparent to those skilled in the art that they will carefully select such or these optional adjuvants or excipients, and / or their amounts, so that the advantageous properties of the compositions according to the invention are not, or substantially not, altered by the intended addition. The composition may contain at least one conventional emulsifier, selected from amphoteric, anionic, cationic, or nonionic emulsifiers, used alone or as a mixture. It may be particularly advantageous that the compositions of the invention are formulated in a sprayable manner. This can be achieved, for example, by formulating a specific emulsion containing a particular combination of excipients.
[0110] Another object of the invention relates to the advantageous ecobiological and / or cosmetic use of the compositions according to the invention for stimulating, improving, restoring, or increasing the expression of genes encoding PEDF proteins and / or the production or synthesis of PEDF proteins.
[0111] In other words, the invention also contemplates:
[0112] - the compositions according to the invention as described above, advantageously ecobiological compositions, for stimulating the expression of genes encoding PEDF proteins and / or the synthesis of PEDF proteins; and / or
[0113] - the compositions according to the invention, advantageously ecobiological compositions, for use in the preparation of medicaments for stimulating the expression of genes encoding PEDF proteins and / or the synthesis of PEDF proteins; and / or
[0114] - methods for stimulating the expression of genes encoding PEDF proteins and / or the synthesis of PEDF proteins, comprising applying, preferably topically applying, the compositions according to the invention, advantageously ecobiological compositions.
[0115] Another object of the invention relates to the advantageous ecobiological use of the compositions according to the invention for the prevention and / or treatment of conditions or symptoms associated with PEDF deficiency and / or decreased PEDF levels relative to reference values.
[0116] In other words, the invention also contemplates:
[0117] - the composition according to the invention, advantageously an ecobiological composition, for the prevention and / or treatment of conditions or symptoms associated with PEDF deficiency and / or decreased PEDF levels relative to reference values; and / or
[0118] - the composition according to the invention, advantageously an ecobiological composition, for the use in the preparation of a medicament for the prevention and / or treatment of conditions or symptoms associated with PEDF deficiency and / or decreased PEDF levels relative to reference values; and / or
[0119] - Methods for preventing and / or treating conditions or symptoms associated with PEDF deficiency and / or decreased PEDF levels relative to reference values, including the application, advantageously topically, of the composition according to the invention, advantageously an ecobiological composition.
[0120] Another object of the invention relates to the advantageous ecobiological use of the composition according to the invention for the prevention and / or counteraction of skin aging (advantageously photoaging) and / or vascular aging (i.e., vascular abnormalities associated with skin aging).
[0121] In the context of the invention, the terms “vascular abnormalities associated with skin aging” and “vascular aging” are used interchangeably, particularly referring to the loss of elasticity of individual blood vessels.
[0122] In other words, the invention also contemplates:
[0123] - the composition according to the invention, advantageously an ecobiological composition, for the prevention and / or counteraction of skin aging (advantageously photoaging) and / or vascular aging; and / or
[0124] - the composition according to the invention, advantageously an ecobiological composition, for the preparation of a medicament for the prevention and / or counteraction of skin aging (advantageously photoaging) and / or vascular aging; and / or
[0125] - a method of preventing and / or counteraction of skin aging (advantageously photoaging) and / or vascular aging, comprising application, advantageously topical application of the composition according to the invention, advantageously an ecobiological composition.
[0126] Another object of the invention relates to the use of the composition according to the invention for the prevention and / or counteraction of skin redness in cosmetic, non-therapeutic, advantageously ecobiological uses.
[0127] In other words, the invention also contemplates:
[0128] - the composition according to the invention, advantageously an ecobiological composition, for the prevention and / or treatment of skin redness; and / or
[0129] - the composition according to the invention, advantageously an ecobiological composition, for the preparation of a medicament for the prevention and / or treatment of skin redness; and / or
[0130] - a method of preventing and / or treating skin redness, comprising applying, advantageously topically applying, the composition according to the invention, advantageously an ecobiological composition.
[0131] Another object of the invention relates to the use of the composition according to the invention for the prevention and / or treatment of excessive vascularization of the skin, advantageously for ecobiological use.
[0132] In other words, the present invention also contemplates:
[0133] - the composition according to the invention, advantageously an ecobiological composition, for the prevention and / or treatment of excessive vascularization of the skin; and / or
[0134] - the composition according to the invention, advantageously an ecobiological composition, for the use in the preparation of a medicament for the prevention and / or treatment of excessive vascularization of the skin; and / or
[0135] - a method of preventing and / or treating excessive vascularization of the skin, comprising application, advantageously topical application according to the invention.The composition of the invention is advantageously an ecobiological composition.
[0136] Another object of the invention relates to the use of the composition according to the invention for the prevention and / or treatment of skin inflammation, advantageously for ecobiological use.
[0137] In other words, the invention also contemplates:
[0138] - the composition according to the invention, advantageously an ecobiological composition, for the prevention and / or treatment of skin inflammation;
[0139] - the composition according to the invention, advantageously an ecobiological composition, for the preparation of a medicament for the prevention and / or treatment of skin inflammation; and / or
[0140] - a method of preventing and / or treating skin inflammation, comprising applying, advantageously topically applying, the composition according to the invention, advantageously an ecobiological composition.
[0141] Another object of the invention relates to the use of the composition according to the invention for the prevention and / or treatment of rosacea, advantageously for ecobiological and / or cosmetic use.
[0142] In other words, the present invention also contemplates:
[0143] - compositions according to the invention, advantageously ecobiological compositions, for the prevention and / or treatment of rosacea;
[0144] - compositions according to the invention, advantageously ecobiological compositions, for the preparation of medicaments for the prevention and / or treatment of rosacea; and / or
[0145] - methods for the prevention and / or treatment of rosacea, comprising the application, advantageously topical application, of the compositions according to the invention, advantageously ecobiological compositions.
[0146] Furthermore, the applicant has identified, in an innovative and unexpected manner, the synthesis of PEDF as a target (i) reduced or inhibited by exposure to UV, particularly UVA; and then (ii) increased or restored by the active ingredients contained in the compositions of the invention, thereby prompting the applicant to develop an innovative, simple, and robust method according to the invention.
[0147] Therefore, according to another aspect, the present invention relates to a method for selecting a compound or a mixture of compounds, advantageously an in vitro or ex vivo method, comprising the following steps:
[0148] a) measuring the content of PEDF protein (pigment epithelium-derived factor) and / or PEDF-encoded nucleic acid in at least one skin cell and / or extracellular space, referred to as a reference value;
[0149] b) inhibiting PEDF synthesis by exposure to ultraviolet (UV) light;
[0150] c) contacting the compound or mixture of compounds with the skin cells;
[0151] d) measuring the content of PEDF protein and / or PEDF-encoded nucleic acid in the skin cells and / or extracellular space, referred to as a “candidate compound” value;
[0152] e) comparing the “candidate compound” value obtained in step d) with the reference value obtained in step a);
[0153] f) When an increase in the content of PEDF and / or PEDF-encoded nucleic acid is observed in step e), the compound or mixture of compounds is selected.
[0154] Step a) of the invention includes measuring the content of PEDF protein and / or PEDF-encoded nucleic acid in at least one skin cell and / or extracellular space, the content representing a baseline state for the intended measurement, rather than “the value tested,” “the test value,” or “the test biological sample,” or “the candidate compound value.”
[0155] Reference values and test values are obtained by performing the same detection, quantification, identification, and other methods. Advantageously, the measurement of the content is performed at the protein level by ELISA, immunohistochemistry, colorimetry, or Western blotting, and / or at the nucleic acid level by in situ hybridization, northern blotting, sequencing, or RT-PCR (more advantageously, RT-qPCR).
[0156] According to one specific embodiment, step b) includes inhibiting the expression of the gene encoding PEDF and / or the production of PEDF mRNA and / or the synthesis of PEDF protein.
[0157] According to the invention, step c) of contacting the compound or mixture of compounds with the skin cells is performed for at least 1 minute, or at least 30 minutes, and at most 120 hours.
[0158] According to one specific embodiment, exposure to UV in step b) includes exposure to the full solar spectrum, specifically UVA and / or UVB and / or the full spectrum. Advantageously, this is:
[0159] - Exposure to UVA, preferably at 750 W / m², with a surface energy of 7.5 J / cm² to 80 J / cm²; or
[0160] - Exposure to the full solar spectrum, preferably at 750 W / m², with a surface energy of 7.5 J / cm² to 80 J / cm².
[0161] Exposure to UV can be performed by any method known to those skilled in the art, for example using a Suntest XLS+ instrument (Atlas France).
[0162] According to an embodiment that can be combined with the foregoing embodiments, step b) is preferably carried out under the following culture conditions for at least 30 minutes and at most 72 hours: 37°C, 5% CO2 and / or saturated humidity.
[0163] According to one embodiment, when the method of the invention is an in vitro method, the contact in step c) can be obtained by topical application of the compound or a mixture of compounds to a skin explant, reconstructed epidermis, or reconstructed skin.
[0164] According to an alternative embodiment, when the method of the invention is an in vitro method, the contact in step c) can be carried out by adding cells to a culture medium, advantageously adding keratinocytes, fibroblasts, or melanocytes.
[0165] According to a specific embodiment, between steps a) and b), the method of the invention further includes applying the compound...The step of contacting the skin cells with the compound or mixture of compounds is advantageously for at least 1 minute, or even at least 30 minutes and up to 120 hours. Advantageously, after the step of contacting the skin cells with the compound or mixture of compounds, and before implementing inhibition of PEDF synthesis by exposure to UV, the culture medium is changed so that it does not contain the compound or mixture of compounds when exposed to UV.
[0166] The content of PEDF protein and / or the nucleic acid (advantageously mRNA) encoding it can be measured by any method known to those skilled in the art.
[0167] Advantageously, the quantification of expressed PEDF protein can be performed by immunohistochemistry on cell sections; by Western blotting; or, it can be performed by an ELISA test, for example, by an ELISA test on the supernatant of cell culture or cell extract, by interpolating the value of the sample's optical density onto a calibration curve obtained by using a series of dilutions (e.g., from 0.1 ng / mL to 10 ng / mL) of recombinant human PEDF protein. In practice, viability testing using MTT, known to those skilled in the art, can be performed on the cell pad. PEDF assay is only used when cell viability is greater than 80% and is correlated with that cell viability value.
[0168] Measurement of the content of messenger ribonucleic acid (mRNA) encoding PEDF can be performed by in situ hybridization of cell sections; by northern hybridization; or practically by RT-qPCR. Advantageously, total RNA is extracted from the tissue, for example using a commercially available kit (such as QIAGEN Rneasy Plus Mini). Total RNA analysis can be performed after extraction to provide the quantity and quality of RNA in the cell extract; this step can be performed using, for example, the Bioanalyzer and RNA 6000 Nano kits. cDNA is generated using the QuantiTect reverse transcription kit (QIAGEN), followed by real-time quantitative PCR at each treatment time, for example using the QuantiFast SYBR Green PCR kit (QIAGEN), and the expression of housekeeping genes (e.g., GAPDH) as controls and the expression of PEDF using specific primers are monitored.
[0169] Therefore, according to one specific embodiment, the PEDF content is measured by ELISA, by immunohistochemistry of cell sections, or by Western blotting; the content of messenger ribonucleic acid (mRNA) encoding PEDF is measured by immunohistochemistry, in situ hybridization of cell sections, northern blotting, sequencing, or RT-PCR, preferably RT-qPCR.
[0170] According to one specific embodiment, the candidate compound is neither a PEDF protein nor one of its bioactive derivatives.
[0171] According to another aspect, the present invention relates to a topical composition, advantageously an ecobiological topical composition, comprising at least one compound or a mixture of compounds selected by means of the method of the present invention described above.
[0172] According to one specific embodiment, the composition is in a galen formulation form suitable for topical application, advantageously cosmetically acceptable, i.e., compatible with skin, mucous membranes, hair, and scalp.
[0173] In particular, the composition is in a galen formulation form suitable for dermal application.
[0174] Thus, the compositions of the present invention are present in one of the galen formulation forms as described above.
[0175] Another object of the invention relates to the use of the composition, advantageously for ecobiological purposes, comprising at least one compound or mixture of compounds selected by the method according to the invention, for:
[0176] - stimulating, improving or substantially increasing the expression of genes encoding PEDF proteins and / or the synthesis of PEDF proteins; and / or
[0177] - preventing and / or treating conditions or symptoms associated with PEDF deficiency and / or decreased PEDF levels relative to reference values; and / or
[0178] - preventing and / or combating skin aging (advantageously photoaging) and / or vascular aging; and / or
[0179] - preventing and / or treating excessive proliferation of skin blood vessels; and / or
[0180] - preventing and / or treating skin inflammation; and / or
[0181] - preventing and / or treating rosacea.
[0182] The following non-limiting examples form an integral part of the invention, and any feature novel relative to the prior art is claimed in its own right and as a general means.
[0183] [Figure 1]: Evaluation of the effect of PGA and L-GAEI alone or in combination on the synthesis of PEDF, which was performed by normal human fibroblasts (NHF) or normal human keratinocytes (NHK) after exposure to UVA at an energy density of 30 J / cm2. Results were obtained from experiments in 3 wells for each condition. Statistical tests were performed against the “untreated, unirradiated” condition (significance: *: p < 0.05; **: p < 0.01; ***: p < 0.001). Detailed Description
[0184] The percentages given in the table below are given as a percentage of the product weight to the total weight of the composition.
[0185] Example 1: Cosmetic Composition - O / W Emulsion as Defined by the Invention
[0186] Table 1 describes the composition according to the invention.
[0187] [Table 1]
[0188]
[0189]
[0190] Example 2: Cosmetic Composition - Gel as Defined in this Invention
[0191] Table 2 describes the compositions according to the present invention. Specification 13 / 17 pages 16 CN 122180498 A
[0192] [Table 2]
[0193]
[0194] Example 3: In vitro evaluation of the effect of the compositions according to the present invention on PEDF synthesis
[0195] 1. Research objective
[0196] The objective of this study is (i) to demonstrate that exposure to UV, especially UVA, reduces PEDF synthesis; and (ii) to determine the ability of two cosmetic active ingredients, alone or in combination, to induce PEDF synthesis after inducing inhibition of PEDF synthesis by exposure to UVA.
[0197] It should be noted that inhibitors of gene expression encoding PEDF and / or PEDF synthesis can be used to identify candidate compounds (or active ingredients) capable of inducing the production and / or increased content of PEDF and / or PEDF-encoding nucleic acids. In other words, after the step of inhibiting the production of PEDF and / or PEDF-encoded nucleic acids, the candidate compound that induces an increase in the content of PEDF and / or PEDF-encoded nucleic acids is classified as a compound according to the purpose of the invention, preferably an ecobiological compound, i.e. suitable for the prevention and / or treatment of aging and / or excessive proliferation of skin blood vessels and / or skin inflammation and / or rosacea, as described above.
[0198] 2. Materials and Methods
[0199] 2.1. Cell Culture
[0200] Normal human fibroblasts (NHF) from Lonza (France) were used in this study. Cells were seeded at a rate of 15,000 cells / well in 96-well plates using complete culture medium (DMEM + 10% FBS + 1% penicillin-streptomycin or P / S). After incubation for 24 hours, the cells were pre-incubated for 24 hours at 37°C and 5% CO2 with the active ingredient diluted in DMEM + 1% P / S. Next, the culture medium was replaced with irradiated medium (Ca-free HBSS), and the cultured cells were irradiated with UVA (750 W / m2, Suntest XLS+, Atlas FRANCE) at a surface energy of 30 J / cm2. After irradiation, the cells were incubated with the active ingredient of the present invention for another 24 hours. The culture supernatant was collected and stored at -80 °C, and then used to quantify the PEDF content in the culture medium by ELISA. Cell viability was evaluated on the cell pad by means of MTT assay, with the aim of normalizing the PEDF results to MTT.
[0201] 2.2. Tested active ingredient specification 14 / 17 pages 17 CN 122180498 A
[0202] The tested active ingredients are listed in Table 3 below.
[0203] [Table 3]
[0204]
[0205] 2.3. Tested PEDF synthesis inhibitors
[0206] Surprisingly, the applicant demonstrated that exposure to UVA can inhibit the synthesis of PEDF and / or PEDF-encoded nucleic acids (see point 1 above). Therefore, UVA exposure was performed at surface energies from 30 J / cm² to 750 W / m².
[0207] 2.4. Determination of PEDF in culture supernatant by ELISA
[0208] Quantification of PEDF in the supernatant was performed by ELISA using an enzyme-linked immunosorbent assay kit (Human Serpin F1 / PEDF DuoSet ELISA, product number: DY1177-05, R&D systems, France) and the reagents recommended by the manufacturer. Optical density (OD) was read at 450 nm using a spectrophotometer. PEDF concentration was calculated based on a standard curve (39 pg / mL to 2500 pg / mL) established with recombinant human PEDF protein. Results are expressed as PEDF / well in pg / mL. Viability was tested on cell pads using MTT assay. PEDF assay was only used when cell viability was greater than 80% and was correlated with that cell viability value.
[0209] 2.5. MTT Cell Viability Assay
[0210] The principle of this assay is based on the use of a tetrazolium salt, MTT ((3-4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), which is reduced to formazan by the mitochondrial enzyme succinate dehydrogenase of living cells. The amount of formazan produced is proportional to the metabolic activity of the cells. This insoluble purple compound must be dissolved in DMSO so that it can be measured spectrophotometrically at 540 nm.
[0211] 2.6. Statistical Analysis
[0212] Quantitative analysis is expressed as mean ± standard deviation. Statistical significance was determined by Student's t-test. Differences were considered statistically significant starting from p < 0.05. (NS: p>0.05; *: p<0.05; **: p<0.01; ***: p<0.001).
[0213] 3. Results and Conclusions
[0214] The results are shown in Figure 1.
[0215] It can be seen that:
[0216] - The "untreated, unirradiated" condition represents the percentage of PEDF synthesis in the absence of stress;
[0217] - The "untreated, irradiated" condition arbitrarily represents 100% PEDF synthesis in the presence of stress;
[0218] - PGA tested at 0.005% and 0.0025% does not have any significant protective effect against UVA stress-induced inhibition of PEDF synthesis, that is, for PGA 0.005% and PGA 0.0025%, PEDF synthesis is -0.9% and +2% respectively (calculated based on the original data);
[0219] - L-GAEI tested at 0.0001% and 0.00005% did not produce any significant protective effect against UVA stress-induced inhibition of PEDF synthesis, i.e., for L-GAEI 0.0001% and L-GAEI 0.00005%, PEDF synthesis was -6.5% and +2.5%, respectively (calculated based on raw data);
[0220] - The two doses of the PGA+L-GAEI combination produced significant protective effects against UVA stress-induced PEDF synthesis, i.e., for PGA 0.005% + L-GAEI 0.0001% and PGA 0.0025% + L-GAEI 0.00005%, PEDF synthesis was +27% and +36%, respectively.
[0221] The synergistic effect between the two substances was calculated by comparing test results measuring the potency of two active substances (in this example: polyglutamic acid or one of its salts as defined in claim 1 (i.e., PGA) and a peptide derivative represented by general formula (I) (i.e., L-GAEI)) and mixtures thereof. The Colby formula (Tammes, 1964; Schuldt, P. H and Lammont 1962) was then used.
[0222] If the measured potency of the mixture is greater than the potency expected according to the Colby formula, a synergistic effect exists. If it is lower than the expected value, an antagonistic effect exists. And, if they are equal, there is no interaction between the two substances.
[0223] Colby formula: E = X + Y - (X × Y) / 100
[0224] Regarding the condition "PGA (0.005%) alone or in combination with L-GAEI (0.0001%)":
[0225] Where X = the effect of compound (or active ingredient) PGA on PEDF synthesis at the test dose (0.005%), i.e., 99.1% PEDF synthesis
[0226] Where Y = the effect of compound (or active ingredient) L-GAEI on PEDF synthesis at the test dose (0.0001%), i.e., 93.5% PEDF synthesis
[0227] Where E = the expected effect of active ingredients PGA and L-GAEI at doses of 0.005% and 0.0001%, respectively, without synergistic effect = (99.1 + 93.5) - [(99.1 * 93.5) / 100] = 99.94%.
[0228] The observed potency of the composition was 127%, which is significantly higher than 99.94% (the expected potency of the composition).
[0229] Regarding the condition "PGA (0.0025%) alone or in combination with L-GAEI (0.00005%)":
[0230] Wherein X= The effect of compound (or active ingredient) PGA on PEDF synthesis at the test dose (0.0025%), i.e., 102% PEDF synthesis
[0231] Where Y = The effect of compound (or active ingredient) L-GAEI on PEDF synthesis at the test dose (0.00005%), i.e., 102.5% PEDF synthesis
[0232] Where E = The expected effects of active ingredients PGA and L-GAEI at doses of 0.0025% and 0.00005%, respectively, without synergistic effect = (102+102.5)-[(102*102.5) / 100] = 99.95%.
[0233] The observed potency of the composition is 136%, which is much higher than 99.95% (the expected potency of the composition).
[0234] These data demonstrate the synergistic effect between components PGA and L-GAEI in the composition according to the invention.
[0235] At the tested concentrations, the individual active ingredients PGA and L-GAEI did not have a significant positive effect on the amount of PEDF. The combination of these active ingredients PGA and L-GAEI had a significant synergistic effect on the amount of PEDF, and therefore also had a significant synergistic effect on the expression and / or synthesis of PEDF.
[0236] References
[0237] Belkacemi, L., and Zhang, SX. (2016). Anti-tumor effects of pigment epithelium-derived factor (PEDF): implication for cancer therapy. A mini- review. J. Exp. Clin. Cancer Res. CR 35, 4.
[0238] Filleur, S., Nelius, T., de Riese, W., and Kennedy, R.C. (2009) Characterization of PEDF: A multi-functional serpin family protein. J. Cell.Biochem.106, 769–775.
[0239] Francis, M.K., Appel, S., Meyer, C., Balin, SJ., Balin, AK., and Cristofalo ,V .J .(2004) .Loss of EPC‑1 / PEDF expression during skin aging in vivo.J.Invest. Dermatol. 122, 1096–1105.
[0240] Grippo, J.O., Simring, M., Coleman, T.A. (2012). Abfraction, abrasion, biocorrosion, and the enigma of noncarious cervical lesions: a 20‑year DESCRIPTION Page 16 of 17 19 CN 122180498 A perspective. J Esthet Restor Dent. 24(1), 10‑23.
[0241] Li and Karin (1999). Is NF‑kappaB the sensor of oxidative stress? FASEB J. 13(10), 1137‑43.
[0242] Limat and Hunziker (2002). Use of epidermal equivalents generated from follicular outer root sheath cells in vitro and for autologous grafting of chronic wounds. Cells Tissues Organs 172(2), 79‑85.
[0243] Poumay, Y., Dupont, F., S Marcoux, S., Leclercq‑Smekens, M., Hérin, M., Coquette, A. (2004). A simple reconstructed human epidermis: preparation of the culture model and utilization in in vitro studies. Arch Dermatol Res. 296(5), 203‑11.
[0244] Tan, K. T., Zheng, G., Hsu, T. T., Wang, Y., Lee, V. W. S., Tian, X., Wang, Y., Cao, Q., Wang, Y., Harris, D. C. H. (2010). Macrophage matrix metalloproteinase‑9mediates epithelial‑mesenchymal transition in vitro in murine renal tubular cells.Am. J. Pathol.176(3) , 1256‑70.
[0245] Tombran‑Tink, J., Lara , N., Apricio, S.E., Potluri, P., Gee, S., Ma , J.‑X., Chader, G., and Barnstable, C.J.(2004) .Retinoic acid and dexamethasone regulate the expression of PEDF in retinal and endothelial cells .Exp .Eye Res.78, 945–955.
[0246] Yamagishi , S .I ., Inagaki , Y ., Nakamura , K ., Abe , R ., Shimizu , T ., Yoshimura , A. Imaizum, T. (2004) .Pigment epithelium‑derived factor inhibits TNF‑a‑induced interleukin‑6 expression in endothelial cells by suppressing N ADPH o xid a se‑med ia ted rea c ti ve o xyg e n s pe cies g ene ra tion .J . Mol.Cell.Cardio.37, 497‑506.
[0247] Yan, B.‑X., Zheng , Y.‑X., Li, W., Chen, J.‑Q., Zhou, J., Cai, S.‑Q., Zheng , M., and Man, X.‑Y. (2018) .Comparative expression of PEDF and VEGF in human epidermal.Discov Med.25(136):47‑56.
[0248] Zamiri , P ., Masli , S ., Streilein , J .W ., and Taylor , A .W .(2006) .PigmentEpithelial growth factor suppresses inflammation by modulating macrophage activation. Invest. Ophthalmol. Vis. Sci. 47, 3912–3918. (Instruction manual, 17 / 17 pages, 20 CN 122180498 A, Figure 1; Instruction manual illustration, 1 / 1 page, 21 CN 122180498 A)
Claims
1. A topical composition, advantageously an ecobiological topical composition, comprising: - One of polyglutamic acid or its salts; and - At least one peptide derivative represented by the following general formula (I): in: -R1 represents a hydrogen atom, an acyl radical, or an acyloxy radical; and -R2 represents the side chain of an α-amino acid selected from the group consisting of tryptophan, glutamic acid, arginine, cysteine, methionine, histidine, and tyrosine.
2. The composition according to claim 1, characterized in that... The molecular weight (Mw) of the polyglutamic acid or one of its salts is from 0.01 kDa to 10 kDa, advantageously from 0.1 kDa to 5 kDa.
3. The composition according to claim 1 or 2, characterized in that... One of the polyglutamic acid or its salts is poly-γ-glutamic acid, advantageously a potassium salt of poly-γ-glutamic acid.
4. The composition according to any one of the preceding claims, characterized in that... The at least one peptide derivative is selected from the group consisting of α-L-glutamyltryptamine, L-tryptamine and L-methionyltryptamine, with α-L-glutamyltryptamine being the most advantageous.
5. The composition according to any one of the preceding claims, characterized in that: -The polyglutamic acid or one of its salts corresponds to the following INCI names: polyglutamic acid, sodium polyglutamate, natto gum, or hydrolyzed poly-γ-glutamic acid potassium; and / or - The at least one peptide derivative is α-L-glutamyltryptamine, which corresponds to CAS No. 478273-36-8 ((4S)-4-amino-5-[[2-(lH-indol-3-yl)ethyl]amino]-5-oxovalerate) and / or corresponds to INCI name glutamylaminoethylindole.
6. The composition according to any one of the preceding claims, characterized in that... The weight ratio of the at least one peptide derivative and one of polyglutamic acid or its salt is 1:200 to 1:10, advantageously 1:100 to 1:
30.
7. The composition according to any one of the preceding claims, characterized in that: - The polyglutamic acid or one of its salts accounts for 0.001% to 10% of the total weight of the composition, advantageously 0.01% to 5%, preferably 0.1% to 2%; and / or - The at least one peptide derivative accounts for 0.00001% to 10% of the total weight of the composition, advantageously 0.0001% to 1%.
8. The non-medical use of the composition according to any one of claims 1 to 7 for combating skin redness and / or skin aging.
9. The composition according to any one of claims 1 to 7, for prevention and / or treatment: - Excessive proliferation of blood vessels in the skin; and / or - Skin inflammation; and / or - Acne vulgaris.
10. An in vitro or extracellular method for selecting a compound or a mixture of compounds, comprising the following steps: a) Measure the content of PEDF protein (pigment epithelium-derived factor) and / or PEDF-encoded nucleic acid in at least one skin cell and / or extracellular space, referred to as the reference value; b) Inhibit PEDF synthesis by exposure to ultraviolet (UV) radiation; c) Contact the compound or mixture of compounds with the skin cells; d) Measure the content of PEDF protein and / or PEDF-encoded nucleic acid in the skin cells and / or extracellular space, referred to as the "candidate compound" value; e) Compare the "candidate compound" value obtained in step d) with the reference value obtained in step a); f) When an increase in the content of PEDF and / or PEDF-encoded nucleic acid is observed in step e), select the compound or a mixture of compounds.
11. The method according to claim 10, characterized in that... The exposure to UV was obtained through the following: - Exposure to UVA, preferably at 750 W / m², with a surface energy of 7.5 J / cm² to 80 J / cm²; or - Exposure to the full solar spectrum, preferably at 750 W / m 2 The surface energy is 7.5 J / cm. 2 Up to 80 J / cm 2 .
